Amylyx Pharmaceuticals Files 8-K
Ticker: AMLX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1658551
Sentiment: neutral
Topics: material-agreement, financials, filing
Related Tickers: AMYX
TL;DR
AMYX filed an 8-K on Jan 10, 2025, for a material agreement & financials. Details TBD.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting the entry into a material definitive agreement and the filing of financial statements and exhibits. The filing does not specify the details of the agreement or the financial information.
Why It Matters
This filing indicates a significant event for Amylyx Pharmaceuticals, potentially involving a new agreement or updated financial disclosures that could impact investors.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could have significant implications, but the lack of specific details necessitates a medium risk assessment.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of Report
- 001-41199 (other) — SEC File Number
- 46-4600503 (other) — IRS Employer Identification No.
- 43 Thorndike St. (address) — Principal executive offices
- Cambridge, MA (location) — Principal executive offices
- 02141 (zip_code) — Principal executive offices
- (617) 682-0917 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Amylyx Pharmaceuticals?
The filing does not specify the details of the material definitive agreement.
What financial statements and exhibits are being filed with this 8-K?
The filing indicates that financial statements and exhibits are being filed, but their specific content is not detailed in the provided text.
When was this 8-K report filed?
This 8-K report was filed on January 10, 2025.
What is Amylyx Pharmaceuticals' principal executive office address?
Amylyx Pharmaceuticals' principal executive office is located at 43 Thorndike St., Cambridge, MA 02141.
What is the SEC file number for Amylyx Pharmaceuticals?
The SEC file number for Amylyx Pharmaceuticals is 001-41199.
Filing Stats: 1,162 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2025-01-10 17:23:08
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $3.50 — on Stock"), at a price to the public of $3.50 per share (the "Offering"). Pursuant to
- $56.9 m — e by the Company, will be approximately $56.9 million, or approximately $65.5 million i
- $65.5 million — imately $56.9 million, or approximately $65.5 million if the option to purchase the Option Sh
Filing Documents
- d917502d8k.htm (8-K) — 31KB
- d917502dex11.htm (EX-1.1) — 153KB
- d917502dex51.htm (EX-5.1) — 7KB
- g917502g0111012046486.jpg (GRAPHIC) — 3KB
- 0001193125-25-004547.txt ( ) — 359KB
- amlx-20250110.xsd (EX-101.SCH) — 3KB
- amlx-20250110_lab.xml (EX-101.LAB) — 17KB
- amlx-20250110_pre.xml (EX-101.PRE) — 11KB
- d917502d8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated January 10, 2025 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: January 10, 2025 By: /s/ James M. Frates James M. Frates Chief Financial Officer